MIPSS70 Prognostic Score System

MIPSS70 is a mutation‑enhanced prognostic model that estimates overall survival in primary myelofibrosis patients aged ≤70 using clinical, cytogenetic, and high‑risk mutation features 1.

Hemoglobin < 10 g/dL
No0Yes+1
Platelet count < 100,000/µL
No0Yes+2
Leukocyte count > 25,000/µL
No0Yes+2
Circulating blasts ≥ 2%
No0Yes+1
Fibrosis grade ≥ 2
No0Yes+1
Constitutional symptoms
No0Yes+1
Absence of CALR type 1-like mutation
No0Yes+1
HMR category
No0Yes+1
Two or more HMR mutations
No0Yes+2

Indicações de Uso

Used in patients ≤70 years with primary myelofibrosis to estimate overall survival risk using clinical, mutational, and (in MIPSS70+) cytogenetic factors 1 [Level I evidence].
Guides timing of allogeneic transplant, as high‑ and very‑high‑risk groups gain clear survival benefit from HSCT over non‑transplant approaches 2 [Level II evidence].

Insights e Precauções

Identifies high‑risk PMF using anemia, leukocytosis, thrombocytopenia, blasts, fibrosis grade, constitutional symptoms, absence of CALR type‑1, and high‑molecular‑risk mutations; high‑risk groups show markedly reduced 5‑year OS (≈29%) in validation cohorts 1 [Level I evidence]. Use cautiously: excludes many ≥70‑year patients, may underperform outside PMF, and additional mutations (CBL/NRAS/KRAS/TP53) do not improve model accuracy 2 [Level II evidence].